JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB273755

Mouse CCL7 knockout RAW 264.7 cell line

Be the first to review this product! Submit a review

|

(0 Publication)

CCL7 KO cell line available to order. KO validated by Western blot. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 85 bp deletion in exon 2. To order both knockout and wild-type control cells: select '2 x 1000000 Cells/vial'. To order only knockout cells: select '1000000 Cells/vial'.
2 Images
Western blot - Mouse CCL7 knockout RAW 264.7 cell line (AB273755)
  • WB

Lab

Western blot - Mouse CCL7 knockout RAW 264.7 cell line (AB273755)

Lanes 1 - 6 : Merged signal (red and green). Green - ab228979 observed at 14 kDa. Red - loading control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37 kDa.

ab228979 was shown to react with MCP3 in RAW 264.7 wild-type cells in Western blot with loss of signal observed in CCL7 knockout sample. Wild-type and CCL7 knockout RAW 264.7 cell lysates were subjected to SDS-PAGE. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab228979 and ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4 ° at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.

All lanes:

Western blot - Anti-MCP3 antibody [EPR22649-155] (<a href='/en-us/products/primary-antibodies/mcp3-antibody-epr22649-155-ab228979'>ab228979</a>) at 1/1000 dilution

Lane 1:

Wild-type RAW 264.7 untreated control cell lysate at 30 µg

Lane 2:

Wild-type RAW 264.7 PMA treated (80 nM, 24 h) plus LPS treated (100 ng/ml, 6 h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 5 h) cell lysate at 30 µg

Lane 2:

Western blot - Mouse CCL7 knockout RAW 264.7 cell line (ab273755)

Lane 3:

CCL7/MCP3 knockout RAW 264.7 untreated cell lysate at 30 µg

Lane 4:

CCL7/MCP3 knockout RAW 264.7 PMA treated (80 nM, 24 h) plus LPS treated (100 ng/ml, 6 h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 5 h) cell lysate at 30 µg

Lane 5:

J774A.1 Glucose treated (138.8 mMol/L, 8 h) plus Brefeldin A treated (5 µg/ml, 6 h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 5 h) cell lysate at 30 µg

Lane 6:

J774A.1 Glucose treated (5.6 mMol/L, 8 h) plus Brefeldin A treated (5 µg/ml, 6 h) and Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) treated (5 µg/ml, 5 h) cell lysate at 30 µg

Predicted band size: 11 kDa

Observed band size: 14 kDa

false

Sanger Sequencing - Mouse CCL7 knockout RAW 264.7 cell line (AB273755)
  • Sanger seq

Supplier Data

Sanger Sequencing - Mouse CCL7 knockout RAW 264.7 cell line (AB273755)

Homozygous : 85 bp deletion in exon 2

Key facts

Cell type

RAW 264.7

Species or organism

Mouse

Tissue

Lymphatic

Form

Liquid

form

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, Homozygous: 85 bp deletion in exon 2

Disease

Carcinoma

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Flow Cyt": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Product details

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "2x1000000Cellsvial": { "sellingSize": "2 x 1000000 Cells/vial", "publicAssetCode":"ab273755-2x1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab275474 Mouse wild-type RAW 264.7 cell line", "number":"AB273755-CMP02" }, { "size":"1 x 1000000 Cells/vial", "name":"ab273755 Mouse CCL7 knockout RAW 264.7 cell line", "number":"AB273755-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab273755-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab273755 Mouse CCL7 knockout RAW 264.7 cell line", "number":"AB273755-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
CCL7
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water for bath approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method all remaining cells into an ultra-low attachment T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent.
5. Once confluent passage into an appropriate flask at a density of 2x105 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • Grow in ultra-low attachment flasks.
  • Do not wash or use dissociation reagent. Cells are semi-adherent. Tap flask sharply to remove adhered cells.
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x105 cells/mL is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The target MCP-3 also referred to as CCL7 is a chemotactic cytokine belonging to the CC chemokine family. Its molecular weight is approximately 11 kDa. MCP-3 is largely expressed by various cell types including monocytes lymphocytes and endothelial cells. This protein plays an important role in immune system signaling. MCP-3 exhibits chemotactic activity for monocytes T lymphocytes and natural killer (NK) cells contributing to immune cell recruitment at sites of inflammation.
Biological function summary

MCP-3 interacts with several chemokine receptors such as CCR1 CCR2 and CCR3 allowing for diverse roles in immune response and inflammation. It functions as both a monomer and in conjunction with other chemokines to form heterodimers aiding in the modulation and fine-tuning of the immune response. The presence of MCP-3 in inflammatory tissues indicates its contribution to directing leukocyte migration and positioning therefore supporting both innate and adaptive immunity.

Pathways

MCP-3 is a component of the chemokine signaling pathway and is significant in the regulation of immune surveillance. It interacts closely with proteins such as CCL2 and CCL3 all of which bind to similar receptors like CCR2 and CCR5. MCP-3's involvement in these pathways supports cellular responses to inflammation and infection and its activity has a direct impact on the mobilization and activation of immune cells.

MCP-3 shows associations with conditions marked by inflammation and immune system dysregulation including rheumatoid arthritis and asthma. The protein's influence in these disorders links to other chemokines like MCP-1 (CCL2) which also recruits monocytes and contributes to chronic inflammation. Disruption in MCP-3 expression or function can aggravate disease states by altering the balance of leukocyte trafficking and exacerbating inflammatory responses.

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Male

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com